Cargando…

Acral erythema arising in patients with atopic dermatitis after dupilumab therapy: A case report of 3 patients

Dupilumab, a monoclonal antibody approved by the U.S. Food and Drug Administration for the treatment of adult patients with moderate-to-severe atopic dermatitis, inhibits interleukins 4 and 13. It is an effective treatment option for atopic dermatitis, but facial redness has been reported as an unex...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Young Jae, Lee, Mi Young, Won, Chong Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819416/
https://www.ncbi.nlm.nih.gov/pubmed/35174052
http://dx.doi.org/10.5415/apallergy.2022.12.e1
_version_ 1784646056361852928
author Kim, Young Jae
Lee, Mi Young
Won, Chong Hyun
author_facet Kim, Young Jae
Lee, Mi Young
Won, Chong Hyun
author_sort Kim, Young Jae
collection PubMed
description Dupilumab, a monoclonal antibody approved by the U.S. Food and Drug Administration for the treatment of adult patients with moderate-to-severe atopic dermatitis, inhibits interleukins 4 and 13. It is an effective treatment option for atopic dermatitis, but facial redness has been reported as an unexpected adverse effect. Although several theories have been proposed to explain the facial redness caused by dupilumab, the underlying mechanism is yet to be verified. To the best of our knowledge, to date, only few reports have described erythema appearance on nonfacial areas after dupilumab treatment. Herein, we report the cases of 3 patients who presented with erythema on their hands and feet after dupilumab injections. The erythema persisted, even when the atopic dermatitis lesions improved. Additional reports are needed to demonstrate the clinical characteristics of postdupilumab acral erythema.
format Online
Article
Text
id pubmed-8819416
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Asia Pacific Association of Allergy, Asthma and Clinical Immunology
record_format MEDLINE/PubMed
spelling pubmed-88194162022-02-15 Acral erythema arising in patients with atopic dermatitis after dupilumab therapy: A case report of 3 patients Kim, Young Jae Lee, Mi Young Won, Chong Hyun Asia Pac Allergy Case Report Dupilumab, a monoclonal antibody approved by the U.S. Food and Drug Administration for the treatment of adult patients with moderate-to-severe atopic dermatitis, inhibits interleukins 4 and 13. It is an effective treatment option for atopic dermatitis, but facial redness has been reported as an unexpected adverse effect. Although several theories have been proposed to explain the facial redness caused by dupilumab, the underlying mechanism is yet to be verified. To the best of our knowledge, to date, only few reports have described erythema appearance on nonfacial areas after dupilumab treatment. Herein, we report the cases of 3 patients who presented with erythema on their hands and feet after dupilumab injections. The erythema persisted, even when the atopic dermatitis lesions improved. Additional reports are needed to demonstrate the clinical characteristics of postdupilumab acral erythema. Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2022-01-10 /pmc/articles/PMC8819416/ /pubmed/35174052 http://dx.doi.org/10.5415/apallergy.2022.12.e1 Text en Copyright © 2022. Asia Pacific Association of Allergy, Asthma and Clinical Immunology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Kim, Young Jae
Lee, Mi Young
Won, Chong Hyun
Acral erythema arising in patients with atopic dermatitis after dupilumab therapy: A case report of 3 patients
title Acral erythema arising in patients with atopic dermatitis after dupilumab therapy: A case report of 3 patients
title_full Acral erythema arising in patients with atopic dermatitis after dupilumab therapy: A case report of 3 patients
title_fullStr Acral erythema arising in patients with atopic dermatitis after dupilumab therapy: A case report of 3 patients
title_full_unstemmed Acral erythema arising in patients with atopic dermatitis after dupilumab therapy: A case report of 3 patients
title_short Acral erythema arising in patients with atopic dermatitis after dupilumab therapy: A case report of 3 patients
title_sort acral erythema arising in patients with atopic dermatitis after dupilumab therapy: a case report of 3 patients
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819416/
https://www.ncbi.nlm.nih.gov/pubmed/35174052
http://dx.doi.org/10.5415/apallergy.2022.12.e1
work_keys_str_mv AT kimyoungjae acralerythemaarisinginpatientswithatopicdermatitisafterdupilumabtherapyacasereportof3patients
AT leemiyoung acralerythemaarisinginpatientswithatopicdermatitisafterdupilumabtherapyacasereportof3patients
AT wonchonghyun acralerythemaarisinginpatientswithatopicdermatitisafterdupilumabtherapyacasereportof3patients